A report released yesterday by the Bipartisan Policy Center, entitled “A Bipartisan Rx for Patient-Centered Care and System-Wide Cost Containment,” contains a smart, forward-looking and no-cost recommendation that could save the government billions, the Generic Pharmaceutical Association said.

A federal court ruling has allowed Actavis to relaunch a generic contraceptive drug, the company said.

Generic drug maker Hospira has appointed Matt Stober as its SVP operations, the company said.

Results of a survey indicate a positive response among patients to redesigned patient medication information distributed to patients at retail pharmacy chains in two states as part of an eight-week program.

A Food and Drug Administration panel has recommended that the agency approve an experimental drug for chronic obstructive pulmonary disease made by GlaxoSmithKline and Theravance, the two companies said.

Generic drug maker Sandoz has launched a generic version of a drug used to treat high blood pressure and angina.

The Food and Drug Administration has approved a new strength of an antibiotic made by Warner Chilcott, the drug maker said.

Does the Obama administration “get it” when it comes to pharmacy’s vital interests and lowering health care costs?

One sometimes wonders. As much as I like the president and many of his ideas and instincts, I’m sometimes stumped by some of the lesser-understood facets of the administration’s health policy, and by the seemingly contradictory sets of priorities promoted by that policy.

Johnson & Johnson's sales increased by 8.5% to $17.5 billion in first quarter 2013, the healthcare products company said Tuesday.

DSN spoke at length with two Catamaran executives — Albert Thigpen, SVP pharmacy operations and industry relations, and Sumit Dutta, SVP and chief medical officer — about the PBM’s new approach to managed pharmacy care and the changes driving that strategy.

Taro Pharmaceutical Industries reported last week that it has received approval from the Food and Drug Administration for its new drug application Topicort (desoximetasone) topical spray, 0.25%.

Generic makers heralded the fiscal year 2014 budget proposed last week by the Obama administration for its embrace of generic drugs, but were critical of its provisions on patent settlements and rebates.